Pharmacodynamic Comparison of Regional Drug Delivery for Non-steroidal Anti-inflammatory Drugs, Using the Rat Air-pouch Model of Inflammation

1995 ◽  
Vol 47 (6) ◽  
pp. 458-461 ◽  
Author(s):  
S. W. MARTIN ◽  
A. J. STEVENS ◽  
B. S. BRENNAN ◽  
M. ROWLAND ◽  
J. B. HOUSTON
1992 ◽  
Vol 36 (3-4) ◽  
pp. C109-C111 ◽  
Author(s):  
D. E. Davies ◽  
A. J. Stevens ◽  
J. B. Houston

Pharmaceutics ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 87 ◽  
Author(s):  
Vincenzo Guarino ◽  
Rosaria Altobelli ◽  
Tania Caputo ◽  
Luigi Ambrosio ◽  
Sergio Caserta ◽  
...  

In recent years, different processing technologies have been engineered to fabricate capsules or particles with peculiar properties (e.g., swelling, pH-sensitive response) at the micro and sub-micrometric size scale, to be used as carriers for controlled drug and molecular release. Herein, the development of cellulose acetate (CA) micro-carriers with mono- (MC) or bi-phasic (BC) composition is proposed, fabricated via electrohydrodynamic atomization (EHDA)—an electro-dropping technology able to micro-size polymer solution by the application of high voltage electrostatic forces. Image analysis allows identification of the process parameters to optimize morphology, in terms of size distribution and shape. Meanwhile, an accurate rheological study has enabled investigating the interface between CA solutions with different viscosities to optimize BC systems. Release tests have confirmed that BC carriers can retain the drug more efficiently in acidic conditions, also providing a more gradual and sustained release until six days, with respect to MC carriers. Hence, all these results have proven that biphasic architecture significantly improves the capability of CA microcarriers to release ketoprofen lysinate, thus suggesting a new route to design core/shell systems for the retarded oral administration of anti-inflammatory drugs.


2021 ◽  
Vol 142 ◽  
pp. 112014
Author(s):  
Kathryn E. Haley ◽  
Talal Almas ◽  
Saeed Shoar ◽  
Shan Shaikh ◽  
Maimoona Azhar ◽  
...  

1992 ◽  
Vol 36 (S1) ◽  
pp. C109-C111
Author(s):  
D. E. Davies ◽  
A. J. Stevens ◽  
J. B. Houston

10.19082/7685 ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 7685-7693
Author(s):  
Tahereh Eteraf-Oskouei ◽  
Atefeh Zabiholahi ◽  
Moslem Najafi ◽  
Bohlool Habibi-Asl

2020 ◽  
Vol 11 (6) ◽  
pp. 363-372
Author(s):  
Jack Masterson ◽  
Brett Kluge ◽  
Aaron Burdette ◽  
George Lewis Sr

Background: Arthritis pain is primarily managed by nonsteroidal anti-inflammatory drugs (NSAIDs), such as diclofenac. Topical diclofenac gel is limited in efficacy due to its limited penetration through the skin. This study investigates the use of a multihour, wearable, localized, sonophoresis transdermal drug delivery device for the penetration enhancement of diclofenac through the skin. Materials & methods: A commercially available, sustained acoustic medicine (sam®) ultrasound device providing 4 h, 1.3 W, 132 mW/cm2, 3 MHz ultrasound treatment was evaluated for increasing the drug delivery of diclofenac gel through a human skin model and was compared with standard of care topical control diclofenac gel. Results: Sonophoresis of the diclofenac gel for 4 h increases diclofenac delivery by 3.8× (p < 0.01), and penetration by 32% (p < 0.01). Conclusion: Sustained acoustic medicine can be used as a transdermal drug-delivery device for nonsteroidal anti-inflammatory drugs.


2018 ◽  
Vol 11 (3) ◽  
pp. 2849-2859 ◽  
Author(s):  
Pramod K. Gavel ◽  
Hamendra S. Parmar ◽  
Versha Tripathi ◽  
Narendra Kumar ◽  
Ankan Biswas ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document